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Introduction {#sec001}
============

High postprandial glucose levels after an oral glucose load are associated with the development of type 2 diabetes (T2D), cardiovascular disease (CVD) as well as increased mortality even in absence of a pre-diabetic condition such as impaired fasting glucose (IFG) \[[@pone.0234237.ref001]--[@pone.0234237.ref008]\]. A causal relationship between high postprandial glucose levels and T2D or CVD appears likely since interventions targeting postprandial glycemia have been shown to prevent these clinical conditions. This has explicitly been shown for pharmacologic interventions with acarbose \[[@pone.0234237.ref009]--[@pone.0234237.ref011]\] and is robustly supported by studies on low glycemic index (GI) diets \[[@pone.0234237.ref012]--[@pone.0234237.ref017]\] as well as experimental data describing possible underlying mechanisms \[[@pone.0234237.ref018]--[@pone.0234237.ref021]\].

Prevention of T2D and CVD are highly relevant and urgent public health issues since rates of obesity and overweight as well as the age of populations increase \[[@pone.0234237.ref001]\]. At the same time carbohydrate-rich foods with a high GI and a high glycemic load (GL), which became widespread throughout the 20th century paralleled by an increasing prevalence of obesity and T2D \[[@pone.0234237.ref022]\], are very popular and commonly available to the consumer \[[@pone.0234237.ref023]\]. These foods bear a high potential of causing pronounced glucose excursions and insulin spikes, which in turn might contribute to the development of T2D and CVD.

The aim of this study was to show efficacy and safety of a novel nutritional supplement drink (hereinafter called "the supplement")---a blend of five specific amino acids (5AA) and chromium picolinate (CrPic) in water, in a two center, double-blinded RCT. The 5AA were selected on basis of their rapid appearance in the blood stream after intake of whey protein \[[@pone.0234237.ref024]\] and chromium picolinate for its potential effect on insulin sensitivity \[[@pone.0234237.ref025]\]. The supplement has been developed to lower postprandial glycemia when consumed with a carbohydrate-rich meal and showed promising results in published \[[@pone.0234237.ref026]\] and unpublished pilot studies.

Methods {#sec002}
=======

Study design {#sec003}
------------

The randomized, double-blind, placebo-controlled, crossover study was performed by KGK Science Inc. at two centers (London ON, Canada and Orlando FL, US). Participants attended two single day periods separated by a 7-day washout period.

Ethics {#sec004}
------

This trial was registered at clinicaltrials.gov as NCT03152682. The registration was done with some delay with respect to patient recruitment, due to lack of clarity who was in charge of the submission. The authors confirm that all ongoing and related trials for this intervention are registered. The investigational product was reviewed by Health Canada and classified as a food. Issuance of a permit to conduct this clinical trial in Canada was therefore not required by Health Canada. Similarly, an Investigational New Drug permit was not required for conduct of the study in the USA. This study was approved for conduct at both the Canadian and the USA sites by the Institutional Review Board (IRB Services, Aurora, Ontario) on March 14, 2017. It was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and its subsequent amendments. Amendments to the protocol were approved on June 14, 2017 and July 27, 2017. Written informed consent was obtained from all participants. The investigational products were produced in the USA and no permit for the import of the investigational product into Canada was required.

Participants {#sec005}
------------

Individuals were recruited from Southwestern Ontario, Canada and Orlando, Florida, using the KGK Science Inc.'s internal participant database along with local electronic and physical advertisement devoid of gender or racial bias. Participants were required to be between 18 and 50 years of age, have a BMI between 25--29.9 kg/m^2^ and be in a good physical and mental condition according to their own perception (on a five point scale from 'poor' to 'excellent'), medical history and laboratory results (full list of inclusion and exclusion criteria in [S1 Table](#pone.0234237.s001){ref-type="supplementary-material"}).

Test product and placebo {#sec006}
------------------------

The supplement was a lightly carbonated drink containing a proprietary blend with molar ratios presented in \[[@pone.0234237.ref026]\] and a total of 2.6 g 5AA (L-Leucine, L-Threonine, L-Lysine Monohydrochloride, L-Isoleucine and L-Valine) as well as 250 mcg CrPic (Good Idea^®^, Good Idea, Inc., Larkspur, CA). Besides water and the active ingredients, the test product also contained citric acid, lemon natural flavor, sodium benzoate and potassium sorbate. The placebo product was identical to the test product with respect to all ingredients, but 5AA and CrPic. The investigational product and placebo were sealed in identically appearing bottles and matched in regard to color, taste and texture.

Intervention {#sec007}
------------

After an overnight fast of 12h, the participants reported to the study facility in the morning. Upon confirmation of participant status and eligibility criteria, an intravenous cannula for repeated blood sampling was placed into the antecubital vein.

Participants started by consuming 175 ml of the supplement or placebo on an empty stomach (time 0), and 3 min later they began with the ingestion of a standardized breakfast meal, alternating between eating and drinking. Three portions of 50 ml each of the supplement or placebo were required to be consumed at min 3, 7 and 11 and the breakfast meal was to be completed by min 14. At the 14 min mark, the final 30 ml of test product or placebo were ingested. The total amount of supplement or placebo was 355 ml. The test meal consisted of white wheat bread (110 g without crust), butter (10 g) and ham (38 g). The calorie and macronutrient composition of the standardized breakfast meal at the London clinical site was: 377 kcal, 47.7g carbohydrates, 14.9 g proteins and 14.1 g fats. The corresponding figures for the Orlando site were: 350 kcal, 45.3 g carbohydrates, 13.1 g proteins and 13 g fats.

Blood samples were collected at 0, 15, 30, 45, 60, 90, 120 and 180 min for glucose (venous and capillary) and insulin (venous) analysis. Capillary blood glucose was measured by the CONTOUR^®^ monitoring system (London site) and the OneTouch^®^ Ultra 2 monitoring system (Orlando site). Quantitative determination of glucose in human serum was conducted via the enzymatic method with hexokinase utilizing the Roche Cobas e701 Analyzer (sensitivity limit 0.5 mmol/L, intra-assay coefficient of variation (CV) 2.7% at 3.1 mmol/L, and 1.4% at 19.8 mmol/L). Quantitative determination of insulin in human serum was conducted via electrochemiluminescence immunoassay utilizing the Roche Cobas e602 Analyzer (sensitivity limit 4 pmol/L, intra-assay CV 7.5% at 106 pmol/L, and 4.5% at 1 357 pmol/L).

Safety endpoints were analyzed in blood drawn at screening and both investigational visits (before starting the actual intervention and associated blood sampling) and included: blood count (hemoglobin, hematocrit, platelet count, red blood cell count, red cell indices, red cell distribution width, white blood cell count, and differentials (neutrophils, lymphocytes, monocytes, eosinophils, basophils)), liver function (alanine transaminase, aspartate transaminase, bilirubin), and kidney function (creatinine, electrolytes (Na, K, Cl)). Besides the blood parameters, also blood pressure and heart rate were monitored. Urine pregnancy tests (Biostrip HCG, Innovatek Medical Inc.) were conducted at both sites for participants of childbearing age during the screening and baseline visits.

Outcome measures {#sec008}
----------------

The pre-defined primary outcome variable was 120-minute incremental area under the curve (iAUC~0-120min~) for venous serum glucose. Time zero (0) indicates the time when the participant started eating the standardized meal and then repeated blood samples were taken until the last one at 120 min post meal start. The iAUC is the area under the curve, above the baseline levels. It corrects for variations in fasting plasma glucose levels within and between individuals and is thus optimal for comparing the effect of a food on blood glucose levels of individuals independently of their fasting plasma glucose. The iAUC is used, among others, for the calculation of the glycemic index \[[@pone.0234237.ref027]\]. Secondary outcome variables for venous sampling were: glucose iAUC~0-180min~; serum insulin iAUC~0-120min~ and iAUC~0-180min~; peak glucose value in 120 minutes (C~max\ 0-120min~) and 180 minutes (C~max\ 0-180min~); time to peak glucose for 120 minutes (T~max\ 0-120min~) and 180 minutes (T~max\ 0-180min~); serum insulin C~max\ 0-120min~ and C~max\ 0-180min~. Secondary outcome variables for capillary measurements were glucose iAUC~0-120min~ and iAUC~0-180min~; C~max\ 0-120min~ and C~max\ 0-180min~; T~max\ 0-120min~ and T~max\ 0-180min~, as well as eating patterns as assessed by a 3-day food record for the weeks prior to days 0 and 8. The difference in each secondary outcome between supplement group and placebo group was tested separately by applying the method described in the Statistical analysis section.

Sample size calculation {#sec009}
-----------------------

A sample size of 30 participants per center (total of 60 participants) was calculated based on an expected iAUC of 66.09 mmol•min/L for the placebo and a pooled standard deviation of 61.50 mmol•min/L from a study by Lustig et al \[[@pone.0234237.ref028]\]. A mean difference of 36.8 mmol/L/min between the investigational product group and the placebo group is expected for the iAUC for each center, assuming a two-sided test with alpha equal to 5%, 80% power and a 20% drop-out rate from enrollment to final, post-baseline measurement.

Randomization {#sec010}
-------------

Randomization numbers were assigned by a blinded investigator per the order of a randomization list generated by [www.randomization.com](http://www.randomization.com) and allocated to their sequence in a decentralized manner in a 1:1 ratio, with a separate randomization list for each site. An un-blinded associate that was not involved in any data capture or study assessments labeled the investigational product. A randomization schedule was created and provided to the investigator indicating the order of randomization. Investigators, other site personnel and participants were blinded to the products.

Statistical analysis {#sec011}
--------------------

All analyses were performed on the pooled data of the two centers. The following analytical populations were defined for the study: Safety population--all participants who received either product and on whom any post-randomization safety information was available; Intention-to-treat (ITT) population--all participants who received either product and on whom any post-randomization efficacy information was available; Per Protocol (PP) population--all participants who consumed 100% of the investigational products, did not have any major protocol violations, and completed all study visits and procedures connected with measurement of the primary variable.

The trapezoid rule was used for calculating iAUC~0-120min~ and iAUC~0-180min~. The trapezoidal rule is a numerical integration method used to approximate the area under a curve. It is widely used to calculate the area under pharmacokinetic curves \[[@pone.0234237.ref029], [@pone.0234237.ref030]\]. Although simple, the trapezoidal rule is a reliable method for calculating iAUC, which has been shown to be more strongly correlated to glycemic response than total AUC \[[@pone.0234237.ref031], [@pone.0234237.ref032]\]. For the iAUC calculations, invalid data points in the ITT and PP analysis were handled by simple imputation methods--averaging values directly adjacent to the missing data point or using a participant's corresponding value from the other study period (pre-ingestion). It was possible to calculate the primary endpoint for 57 participants. Calculations for all other outcome variables were performed on the original data set without imputation. The between group changes from pre-ingestion were analyzed by a mixed model repeated measures analysis of variance. The model included subject as a random effect, with fixed effects of group, sequence, and visit. The p-values for each change was derived by a linear contrast statement of this model. P-values ≤ 0.05 were considered statistically significant. All statistical analysis was completed using the R Statistical Software Package Version 3.2.2 (R Core Team, 2015) and SAS version 9.3 (Cary, North Carolina) for Microsoft Windows.

Results {#sec012}
=======

The participant recruitment began in March 2017 and the study was completed by August 2017. In order to recruit 60 men and women in equivalent numbers and according to pre-defined inclusion and exclusion criteria, a total of 110 candidates needed to be screened. The participant flow is outlined in [Fig 1](#pone.0234237.g001){ref-type="fig"}.

![Participant flow.](pone.0234237.g001){#pone.0234237.g001}

The ITT population included 60 participants (32 female, 28 male) from which 12 were excluded, with a resulting PP population of 48 participants (23 female, 25 male). Baseline characteristics are presented in [Table 1](#pone.0234237.t001){ref-type="table"}. Out of the 12 excluded participants, seven were from the supplement → placebo sequence and five from the placebo → supplement sequence. The reasons for the exclusions were: starting antibiotic treatment (n = 1), delayed or missing blood samples (n = 3), non-adherence to the protocol (n = 2), fainting (n = 1) and wish to terminate the participation before second trial day (n = 5).

10.1371/journal.pone.0234237.t001

###### Participant characteristics at screening[^1^](#t001fn001){ref-type="table-fn"}.

![](pone.0234237.t001){#pone.0234237.t001g}

                                              ITT population (*n* = 60)   PP population (*n* = 48)
  ------------------------------------------- --------------------------- --------------------------
  Gender, *n* (%)                                                         
   Female                                     32 (53%)                    23 (48%)
   Male                                       28 (47%)                    25 (52%)
  Alcohol consumption status, *n* (%)                                     
   None                                       21 (35%)                    17 (35%)
   Occasional                                 26 (43%)                    21 (44%)
   Weekly                                     13 (22%)                    10 (21%)
  Smoking status, *n* (%)                                                 
   Ex-smoker                                  5 (8%)                      3 (6%)
   No                                         55 (92%)                    45 (94%)
  Health questionnaire, *n* (%)                                           
   Excellent                                  22 (37%)                    18 (38%)
   Very good                                  27 (45%)                    21 (44%)
   Good                                       11 (18%)                    9 (19%)
  Race, *n* (%)                                                           
   Western European white                     28 (47%)                    21 (44%)
   Black or African American                  15 (25%)                    12 (25%)
   Other                                      17 (28%)                    15 (31%)
  Age, yrs (SD)                               34.6 (10.4)                 35.5 (10.5)
  Weight, kg (SD)                             79.7 (10.2)                 80.8 (10.7)
  BMI, kg/m^2^ (SD)                           27.4 (1.59)                 27.5 (1.59)
  Fasting venous blood glucose, mmol/L (SD)   4.93 (0.42)                 4.95 (0.42)
  HbA1c, % (SD)                               5.48 (0.33)                 5.47 (0.31)
  Systolic blood pressure, mmHg (SD)          119.8 (8.9)                 117.7 (9.0)
  Diastolic blood pressure, mmHg (SD)         76.2 (8.1)                  75.8 (8.7)
  Heart rate, bpm (SD)                        69.0 (11.1)                 69.2 (11.2)

^1^ Values are *n* (%), or means (SD)

The glucose and insulin responses are presented in [Fig 2](#pone.0234237.g002){ref-type="fig"} and [Table 2](#pone.0234237.t002){ref-type="table"}.

![Postprandial glucose and insulin responses.\
Glucose and insulin responses for the ITT (*n* = 54--58, for different time points) and PP (*n* = 48) populations respectively after intake of a high carbohydrate sandwich meal with supplement or placebo. Data are expressed as means ± SE. Asterisc (\*) indicates a significant difference between treatments (p\<0.05) at the respective time point.](pone.0234237.g002){#pone.0234237.g002}

10.1371/journal.pone.0234237.t002

###### Glucose and insulin responses for ITT and PP populations^1^.

![](pone.0234237.t002){#pone.0234237.t002g}

  ---------------------------------- ---------------- ------------- ---------------------- ---------------------- ------------ ------- -------- ------- ------- -------- -----------
                                     **Supplement**   **Placebo**   **Group Difference**   **95% CI**                                                                    
  **ITT population**                 *n*              Mean          SE                     *n*                    Mean         SE      Mean     SE      Upper   Lower    *p-v*alue
  ***Serum glucose***                                                                                                                                                    
  **iAUC~0-120\ min~, mmol/L•min**   54               52·20         6·79                   58                     68·72        6·62    -16·54   6·71    -3·08   -30·01   0·017
  **iAUC~0-180\ min~, mmol/L•min**   54               62·44         8·42                   58                     79·07        8·19    -16·63   8·56    0·55    -33·81   0·058
  **C~max0-120\ min~, mmol/L**       54               6·10          0·12                   58                     6·45         0·12    -0·35    0·09    -0·17   -0·53    \<0·001
  **T~max0-120\ min~, min**          54               51·04         2·49                   58                     52·29        2·85    -1·25    5·32    5·32    -7·82    0·704
  ***Serum insulin***                                                                                                                                                    
  **iAUC~0-120\ min~, pmol/L•min**   54               15 803        1 589                  58                     14 523       1 556   1 279    1 334   3 958   -1 399   0·342
  **iAUC~0-180\ min~, pmol/L•min**   54               19 361        1 908                  58                     17 253       1 869   2 108    1 589   5 298   -1 083   0·191
  **C~max\ 0--120\ min~, pmol/L**    54               380·99        35·19                  58                     345·70       34·63   35·29    25·58   86·66   -16·07   0·174
  **T~max\ 0--120\ min~, min**       54               59·38         3·43                   58                     58·78        3·33    0·60     3·76    8·16    -6·95    0·873
                                     **Supplement**                 **Placebo**            **Group Difference**   **CI 95%**                                             
  **PP population**                  *n*              Mean          SE                     *n*                    Mean         SE      Mean     SE      Upper   Lower    *p*-value
  ***Serum glucose***                                                                                                                                                    
  **iAUC~0-120\ min~, mmol/L•min**   48               53·73         7·26                   48                     66·48        7·26    -12·75   6·95    1·24    -26·74   0·073
  **iAUC~0-180\ min~, mmol/L•min**   48               62·36         8·72                   48                     74·37        8·72    -12·01   8·91    5·93    -29·94   0·185
  **C~max\ 0--120\ min~, mmol/L**    48               6·12          0·14                   48                     6·42         0·14    -0·29    0·09    -0·12   -0·47    0·002
  **T~max\ 0--120\ min~, min**       48               49·30         2·98                   48                     49·61        2·98    -0·31    3·22    6·17    -6·79    0·923
  ***Serum insulin***                                                                                                                                                    
  **iAUC~0-120\ min~, pmol/L•min**   48               14 833        1 607                  48                     13 546       1 607   1 268    1 416   4 119   -1 582   0·375
  **iAUC~0-180\ min~, pmol/L•min**   48               17 737        1 791                  48                     15 713       1 791   2 024    1 719   5 483   -1 436   0·245
  **C~max\ 0--120\ min~, pmol/L**    48               357·15        35·81                  48                     324·42       35·81   32·73    26·62   86·30   -20·85   0·225
  **T~max\ 0--120\ min~, min**       48               59·50         3·48                   48                     58·17        3·48    1·33     3·96    9·29    -6·64    0·739
  ---------------------------------- ---------------- ------------- ---------------------- ---------------------- ------------ ------- -------- ------- ------- -------- -----------

In the ITT population, the supplement led to a 24% reduction in venous serum glucose iAUC~0-120\ min~ (p = 0.03) as the primary outcome measure as well as a 5.4% reduction in C~max\ 0--120~ (p\<0.01) as compared to placebo. There were significant differences in serum glucose between placebo and the supplement at 30, 45, 60, 90 and 120 minutes (reduction by 4%, 3%, 5%, 6% and 4% respectively). No significant differences in the iAUCs for insulin, T~max~ or iAUC for capillary measurements were observed.

In the PP population a 4.5% reduction in C~max\ 0--120~ (p\<0.01) could be documented. There were significant reductions in serum glucose by the supplement compared with placebo at 30, 45 and 60 minutes (-4%, -4% and -5% respectively). No significant differences in the iAUCs for venous serum glucose or insulin as well as T~max~ or iAUC for capillary measurements, were observed.

An analysis of subgroups was performed in the PP population. Pronounced effects were observed in the middle-aged group (40--50 years old, n = 23) with a 30% reduction in venous glucose iAUC~0-120\ min~ (p = 0.006) and a 5% reduction in C~max~ (p = 0.004) after the supplement compared to placebo. The other subgroups (gender, race) did not show any significant changes in the primary endpoint.

There were no severe adverse events, as categorized by the Medical Dictionary for Regulatory Activities, version 17. Out of 19 mild to moderate adverse events (AE) recorded in 16 individuals experiencing these events, three events were categorized as possibly related to the supplement (one nervous system disorder and two gastrointestinal disorders) and one as possibly related to placebo (vascular disorder). All AEs were resolved by the end of the study without requiring medical treatment or hospitalization.

Discussion {#sec013}
==========

In this controlled clinical trial, we show a significant reduction of the serum glucose iAUC in healthy overweight subjects after a mixed meal consumed together with the supplement, compared to placebo. There are different ways in which the supplement could beneficially influence the glucose metabolism and health in the target population of individuals that are not yet affected by cardiovascular disease or diabetes. From a GI point of view \[[@pone.0234237.ref033]\], the supplement was able to reduce the overall GI of the high glycemic test meal. Although there is still some controversy on the role of low GI food and meals \[[@pone.0234237.ref012], [@pone.0234237.ref034]\], most studies comparing diets with different GI´s favor the ones with a lower GI in regards to the development of T2D \[[@pone.0234237.ref012]--[@pone.0234237.ref017], [@pone.0234237.ref035], [@pone.0234237.ref036]\].

Elevated postprandial glucose has been identified as an important risk factor for developing T2D as well as CVD and even overall mortality in individuals without impaired glucose tolerance (IGT) or T2D. The factual endpoints studied in these epidemiological studies were the 60 and 120 minutes glucose values after a standardized glucose load varying between 50g and 100g of glucose \[[@pone.0234237.ref001]--[@pone.0234237.ref008]\]. This study showed significant differences for venous glucose at 30, 45, 60 and 90 minutes in favor of the supplement, thus showing a significant reduction of the surrogate risk factor 60-minute postprandial glucose. The use of a mixed meal as opposed to glucose solutions tests efficacy of the supplement closer to a real-life scenario.

There is ample evidence for a causal relationship between elevated postprandial glucose and the development of T2D and CVD. Experimental evidence on a cellular level shows that an induction of endothelial dysfunction by postprandial hyperglycemia is most likely a consequence of increased oxidative stress \[[@pone.0234237.ref018]--[@pone.0234237.ref021]\]. In human studies, postprandial glucose excursions have been shown to correlate with the extent of atherosclerosis \[[@pone.0234237.ref021]\]. Interventions targeting postprandial glycemia have been shown to prevent atherosclerosis but also the development of T2D \[[@pone.0234237.ref009]--[@pone.0234237.ref011]\] and possibly even cardiovascular events \[[@pone.0234237.ref009], [@pone.0234237.ref010]\].

Participants in this study were mostly overweight and the glucose lowering effect of the supplement was pronounced in the older subgroup (40--50 yrs) showing a significant and impressive 30% reduction of iAUC~0-120\ min~ glucose. Since overweight and increasing age are the main risk-factors for developing diabetes \[[@pone.0234237.ref001]\], efficacy of the supplement has been shown in a group, in which diabetes prevention is highly relevant.

The exact mechanisms leading to the observed effects of the supplement on postprandial glucose are not completely clear. Chromium is, however, known to play a role in glucose metabolism, possibly by potentiating insulin interaction with its receptor via binding of a low molecular chromium binding protein \[[@pone.0234237.ref037]--[@pone.0234237.ref039]\]. Yet, its role in improving glucose metabolism as a supplement is not well described in controlled clinical studies, most of which were performed in patients with T2D \[[@pone.0234237.ref040]--[@pone.0234237.ref043]\]. Milk and whey protein are known to stimulate insulin \[[@pone.0234237.ref044]--[@pone.0234237.ref050]\] and thus reduce the postprandial glucose response to a glucose solution \[[@pone.0234237.ref045], [@pone.0234237.ref047]--[@pone.0234237.ref051]\]. However, in the case of single amino acids, the insulinogenic effect is not attributable to all amino acids \[[@pone.0234237.ref052]--[@pone.0234237.ref055]\] and requires higher doses than the ones used here \[[@pone.0234237.ref052], [@pone.0234237.ref053], [@pone.0234237.ref056]--[@pone.0234237.ref058]\]. Hence, the iAUC for insulin was not significantly increased by the supplement compared to placebo and there was only an indication of a trend towards an earlier insulin response when looking at insulin iAUC´s. Studies looking at insulin and the development of T2D or IGT suggest that a pronounced first-phase insulin response compared to a late insulin increase could be beneficial \[[@pone.0234237.ref055], [@pone.0234237.ref059]--[@pone.0234237.ref061]\]. In addition it has been described, that proteins and amino acids have a distinct effect on gastric emptying, possibly delaying the glucose uptake \[[@pone.0234237.ref062]--[@pone.0234237.ref064]\]. A 'priming' of the stomach with the first sips of the supplement leading to a slowing of gastric emptying and a better insulin homeostasis could contribute to the effects on postprandial glucose observed. Further research will have to substantiate these hypotheses.

The limitations of this study include missing values due to the high number of blood draws required for each participant and thus the need for imputation of some results when performing the iAUC calculation in the ITT analysis. Another limitation is the lack of data on menstrual cycle for the female participants, since it is known that blood glucose regulation differs between the follicular and luteal phases \[[@pone.0234237.ref065]\]. Overall, there were no significant effects when looking at the capillary blood measurements. This can be explained by the use of patient glucometers, which are known for their imprecision \[[@pone.0234237.ref066], [@pone.0234237.ref067]\] and cannot be expected to produce reliable data for the calculation of differences in glucose iAUC. This is surely a systematic problem for the analysis of this secondary end point. However, in a previous study of an early version of the supplement, professional glucometers used for capillary blood glucose measurements showed significant reductions of postprandial glucose, in line with that shown for venous glucose in this study \[[@pone.0234237.ref026]\]. Another limitation of this study was the variability in brands of bread used for the standardized test meal between the Canadian and American sites. This resulted in a slight difference in fiber content between the meals, with the Canadian brand having 2 grams more dietary fiber than the US brand. However, the macronutrient and caloric content of the test meals remained relatively similar between sites and individuals at each center received the same brand in the supplement and placebo test meal.

In conclusion, the supplement drink tested in this study efficiently reduced the postprandial glucose excursions after a meal with a high carbohydrate content without causing any adverse events. Future studies will have to evaluate whether regular consumption of the supplement improves markers of disease or might even prevent the development of diabetes. Effects on satiety and food cravings will also have to be studied. Definition of the mechanisms involved in the observed effects will help to develop supplements that could not only be used for the prevention of diabetes but may also be an option for dietary interventions in metabolic disease.
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As per the journal's editorial policy, please include in the Methods section of your paper:

1\) your reasons for your delay in registering this study (after enrolment of participants started);

2\) confirmation that all related trials are registered by stating: "The authors confirm that all ongoing and related trials for this drug/intervention are registered".

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

3\. In your Methods section, please provide additional information about the participant recruitment method and on the health questionnaire used; moreover, please provide a link or a reference for the proprietary blend used.

4\. Please provide the necessary documentation confirming that the IRB service used had jurisdiction in the United States of America.

5\. Thank you for stating the following in the Financial Disclosure section:

\'The study was funded in full by Aventure AB/Double Good AB, Sweden.\'

We note that one or more of the authors are employed by a commercial company: starScience GmbH & Aventure AB.

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Additional Editor Comments (if provided):

We note that in the demographic classification used, Asians, Hispanics and Aboriginal are included in the\"North White Americans\" group. As these populations show different risk levels for diabetes and CVDs, please clarify why it was chosen to group them together. 

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a well conducted and reported study. There were a number of issues related to the statistical design and analysis which I would recommend that the authors report differently, with reasons:

\(1\) The primary outcome should be explained a bit more clearly. The authors should, in a brief paragraph, describe how the iAUC is obtained. Where they cite methods of calculating it (e.g the trapezoid rule), they should explain why they have chosen this method instead of others.

\(2\) The study has several secondary outcomes. The authors should describe any considerations they have made to deal with multiple testing.

\(3\) The sample size calculation is poorly described. The authors say that it was calculated based on an expected effect size of 35.8mmol/L/min; however, this is not an effect size (a standardised difference). The authors should say what the expected mean value of the outcome was expected to be in the control group, along with the standard deviation and the difference in the mean outcome value expected due to the intervention, with justification.

\(4\) In the analysis of the outcome, the authors used a mixed model repeated measures ANCOVA with the pre-treatment value as a covariate. When using this approach, the effect of the pre-treatment value should be fixed to zero - the authors do not appear to have done this.

\(5\) In Table 1 the authors have presented a comparison of the characteristics of participants included in the ITT vs. PP populations. While this is useful information, what the authors should have presented in this table is a comparison of the same characteristics of individuals in the intervention group to those in the placebo group.

\(6\) In Table 2, the authors should report the mean value of the outcome and the standard errors (not standard deviation - SDs are reported for description (e.g. baseline tables), but SEs are reported for inference). They should also report the difference in outcome and the confidence intervals for the difference along with the p-value. Please see the report of other clinical trials, e.g. (<https://journals.plos.org/plosmedicine/article/figure?id=10.1371/journal.pmed.1001518.t003>) to see how this should be done.

\(7\) Instead of cite the treatment effect as a percent reduction in serum glucose, the authors should report the absolute reduction in serum glucose, along with the 95% confidence intervals and p-value. If the authors want to express this as a relative reduction, this should be done in the discussion, or as an alternative (but not replacement for the absolute reductions). If reporting the relative reductions, the confidence intervals for these reductions should also be reported.

\(8\) The authors should avoid the +/- designation when reporting numerical results as it is very misleading and actually quite meaningless in many of the contexts it has been used. For example, in the abstract, it is difficult to tell whether a decrease in glucose iAUC-120min 49.5 +/- 47 refers to decreases varying from 2.5 to 96.5 or whether 47 is the IQR. Similarly in Table 1, mean age in the ITT population is reported as 34.6 +/- 10.4 with a footnote indicating that the +/- are SD; however, what does a mean +/- the SD really mean in practical terms? This should not be reported in this manner. Instead, the abstract should be reporting the mean reductions and their 95% confidence intervals; this has a very clear statistical meaning. When reporting the table of characteristics where it is typical to report means and their SDs, the authors should simply report the mean followed by the SD in brackets and indicate so in the footnote, e.g. 34.6 (10.4). It may be common to use the +/- designation in the literature, but because of the inconsistent way in which this is done (some use it to mean ranges, others IQRs, yet others SDs, mostly without clear indication), it is best to avoid this. See <https://journals.plos.org/plosmedicine/article/figure?id=10.1371/journal.pmed.1001594.t001> for an example of how to report means SDs and ranges for descriptive purposes.

Reviewer \#2: Aim of the study was that to evaluate postprandial responses in serum glucose and insulin levels in a cohort of overweight subjects of both genders, treated with a supplement consisting in 2.6 g of amino acids (L-Leucine, L-Threonine, L-Lysine, L-Isoleucine and L-Valine) and 250 mcg of chromium picolinate vs. placebo. In the intention-to-treat-analysis (n = 60), the supplement significantly decreased glucose levels (as iAUC0-120 min, iAUC0-180 min and Cmax), without affecting those of insulin. The treatment was well tolerated.

The study is well designed and the results are adequately presented. Due to the paucity of biochemical parameters (serum glucose and insulin), the manuscript should be submitted as a rapid communication in a journal of nutrition sciences. Furthermore, some major and minor issues should be solved.

Comments

1\. In the Introduction the rationale has not been clearly reported. In particular, there is no information regarding the reasons for which the Authors chose the specific ingredients of the supplement. For instance, the gastroenteropharmacological properties of the selected amino acids (branched-chain amino acids?) should be mentioned.

2\. Few biochemical parameters have been measured. Only serum levels of glucose and insulin. To understand the biochemical or pharmacological mechanisms underlying the hypoglycemic effect of the supplement, the Authors should evaluate circulating levels of some gastrointestinal peptides, particularly incretins such as GLP-1, which exert insulinotropic effects and reduce gastric empting. See the article by Rigamonti et al., Nutrients, 2019;11(2). pii: E247. doi: 10.3390/nu11020247.

3\. The results referring to glycaemia measured with glucometer, which is defined an "imprecise" method by the Authors (pag. 17 -- line 81), should be removed, because they do not add anything.

4\. The Authors should explain the differences in results obtained in the per-protocol analysis vs in the intention-to-treat analysis.

5\. In the Abstract the Authors should state that subjects were overweight and of both genders. Not only in the conclusions.

6\. The Authors should report the phase of the menstrual cycle during which the experimental tests were performed in female subjects.

7\. In the final part of the Discussion, when reporting limitations of the study, the Authors state that fiber content in bread used in the two centers is different. An appropriate statistical analysis should rule out the potential "interfering" effect of this factor.

8\. Numbers of females/males should be reported in the section of Participants (pag. 4).

9\. The exact doses of the single amino acids should be indicated. Not simply 2.6 g of amino acids (L-Leucine, L-Threonine, L-Lysine, L-Isoleucine and L-Valine).

10\. Pag. 5: protein/fat should be replaced with proteins/fats.

11\. Sensitivity and intra-/inter-assay coefficients of variation of the analytical methods for glucose and insulin should be indicated.

12\. Pag. 6; the safety endpoints were evaluated at the three visits. Please, specify these time points.

13\. Fig. 1 is of low resolution and difficult to read. Please, improve the quality of this figure.

14\. Pag. 14 -- Line 1: "Lead" should be "led".

15\. Pag. 14 -- Line 16; what are the "other subgroups"? Please, specify.

16\. Pag. 14 -- Line 19: the Authors state that adverse events were categorized as possibly related to supplement or placebo. What system of categorization (or algorithm) was used?

17\. Pag. 15 -- line 33: where was the acronym IGT (impaired glucose tolerance) abbreviated?

18\. Pag. 16 -- lines 65-68: the Authors discuss the results by citing "unpublished" results. This is scientifically not appropriate.

Reviewer \#3: This clinical trial was designed to evaluate the efficacy of a nutritional supplement to lower blood glucose levels after a meal in health individuals. The study was well-conducted and the data were clearly described. I only have few comments, but that should be included in the revised manuscript:

1\) A conflicting result is regarding the lack of changes when blood glucose levels were evaluated using glucometers, compared to enzymatic methods that determined serum glucose. The authors argued that regular glucometers used in the present study are imprecise, but I personally think that this argument is not necessarily valid. Anyway, I think that the authors should include the information of the lack of differences in blood glucose levels when using glucometers in the Abstract. Thus, the readers can be informed that the improvement in glucose homeostasis was verified by one method of analysis but was not confirmed by data obtained using glucometers.

2\) The adverse events should be described in Results. They are only briefly mentioned without explaining what they refer to.

3\) Although I agree that this is not required for this clinical trial, I recommend that the authors measure GI-secreted hormones (e.g., GLP-1, PYY, GIP or ghrelin) during their trials to try to determine whether the supplement could have its effects via humoral mechanisms.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Jose Donato Junior

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234237.r002

Author response to Decision Letter 0

13 Jan 2020

Journal Requirements

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Answer: All format requirements have been reviewed and manuscript revised accordingly.

2\. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal's editorial policy, please include in the Methods section of your paper:

1\) your reasons for your delay in registering this study (after enrolment of participants started);

2\) confirmation that all related trials are registered by stating: "The authors confirm that all ongoing and related trials for this drug/intervention are registered".

Please also ensure you report the date at which the ethics committee approved the study as well as the complete date range for patient recruitment and follow-up in the Methods section of your manuscript.

Answer: The task of registering the study had unfortunately fallen between chairs of the authors and the contracted research organization and that caused the delay. A sentence explaining this have been added on page 4. The date of IRB approval is stated on page 4. The date range for recruitment and follow-up is stated under Results on page 9.

3\. In your Methods section, please provide additional information about the participant recruitment method and on the health questionnaire used; moreover, please provide a link or a reference for the proprietary blend used.

Answer: Information on recruitment method and self rated health has been added on pages 4-5. Reference to previous publication of proprietary blend has been added on page 5.

4\. Please provide the necessary documentation confirming that the IRB service used had jurisdiction in the United States of America.

Answer: In the uploaded IRB approval of 16 March 2017 there is a section called Compliance statement/Attestation where it is stated that the IRBs of IRB Services are registered with OHRP and FDA. According to the CRO used for the study, IRB Services Inc (now Advarra) was a part of Cheasepeake Bay IRB (a US company). It has jurisdiction in both countries.

5\. Thank you for stating the following in the Financial Disclosure section:

\'The study was funded in full by Aventure AB/Double Good AB, Sweden.\'

We note that one or more of the authors are employed by a commercial company: starScience GmbH & Aventure AB.

1\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors<http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Answer: Funding and Competing Interests Statements have been updated in the cover letter.

Additional Editor Comments (if provided):

We note that in the demographic classification used, Asians, Hispanics and Aboriginal are included in the\"North White Americans\" group. As these populations show different risk levels for diabetes and CVDs, please clarify why it was chosen to group them together.

Answer: The aim of the study was to recruit 50% "North White Americans" and 50% "African Americans" and not making any further classifications. It turned out to be more difficult then anticipated to recruit African Americans and despite numerous efforts we ended up with only 25% African Americans, making that group too small to draw firm conclusions from. The "North White Americans" are presented as 47% "Western European Whites" and 28% "Other" but no classifications were used for the primary analysis in the study. It would not make sense from a statistical power point of view.

Response to reviewers

Reviewer \#1: This is a well conducted and reported study. There were a number of issues related to the statistical design and analysis which I would recommend that the authors report differently, with reasons:

\(1\) The primary outcome should be explained a bit more clearly. The authors should, in a brief paragraph, describe how the iAUC is obtained. Where they cite methods of calculating it (e.g the trapezoid rule), they should explain why they have chosen this method instead of others.

Answer: The trapezoid rule was used for calculating iAUC0-120min and iAUC0-180min. The trapezoidal rule is a numerical integration method used to approximate the area under a curve.

Explanations and references have been added on pages 6 and 8.

\(2\) The study has several secondary outcomes. The authors should describe any considerations they have made to deal with multiple testing.

Answer: The secondary outcomes are all aimed at different aspects of postprandial glycemia as it is the primary endpoint. They can be clustered in venous results, capillary results and insulin. The magnitude and significance of the secondary endpoints in this case can either support or oppose the result obtained as the primary endpoint. We present the results and discuss these accordingly.

\(3\) The sample size calculation is poorly described. The authors say that it was calculated based on an expected effect size of 35.8mmol/L/min; however, this is not an effect size (a standardized difference). The authors should say what the expected mean value of the outcome was expected to be in the control group, along with the standard deviation and the difference in the mean outcome value expected due to the intervention, with justification.

Answer: The description has been revised.

\(4\) In the analysis of the outcome, the authors used a mixed model repeated measures ANCOVA with the pre-treatment value as a covariate. When using this approach, the effect of the pre-treatment value should be fixed to zero - the authors do not appear to have done this.

Answer: We have contacted the responsible CRO (KGK Science) and addressed the issue with the responsible biostatistician. The biostatistician informed us that there was an error in the methods description in the study report and that in fact an ANOVA and not an ANCOVA was performed (thus no covariate was involved in the first place). In this process the authors asked the CRO to provide additional details on the iAUC calculation and noted that in the ITT group iAUC has been calculated in 3 cases despite missing adjacent glucose values. These 3 iAUC values were excluded from the analysis and the biostatistician provided updated results (see Table 2, Figure 2). Some strength of the association was lost in the process, but statistical significance remained. The original data including iAUCs calculated by the CRO will be provided.

The method used has been updated/revised accordingly.

\(5\) In Table 1 the authors have presented a comparison of the characteristics of participants included in the ITT vs. PP populations. While this is useful information, what the authors should have presented in this table is a comparison of the same characteristics of individuals in the intervention group to those in the placebo group.

Answer: Since it is a cross-over study, all participants had both the supplement and placebo meals. Thus, there are no comparisons to be made between groups and we find it informative to show how the characteristics change from the higher number of participants included in the ITT population compared with the reduced number of participants in the PP population.

\(6\) In Table 2, the authors should report the mean value of the outcome and the standard errors (not standard deviation - SDs are reported for description (e.g. baseline tables), but SEs are reported for inference). They should also report the difference in outcome and the confidence intervals for the difference along with the p-value. Please see the report of other clinical trials, e.g. (<https://journals.plos.org/plosmedicine/article/figure?id=10.1371/journal.pmed.1001518.t003>) to see how this should be done.

Answer: Table 2 has been revised accordingly.

\(7\) Instead of citing the treatment effect as a percent reduction in serum glucose, the authors should report the absolute reduction in serum glucose, along with the 95% confidence intervals and p-value. If the authors want to express this as a relative reduction, this should be done in the discussion, or as an alternative (but not replacement for the absolute reductions). If reporting the relative reductions, the confidence intervals for these reductions should also be reported.

Answer: Presentation of results have been revised accordingly.

\(8\) The authors should avoid the +/- designation when reporting numerical results as it is very misleading and actually quite meaningless in many of the contexts it has been used. For example, in the abstract, it is difficult to tell whether a decrease in glucose iAUC-120min 49.5 +/- 47 refers to decreases varying from 2.5 to 96.5 or whether 47 is the IQR. Similarily in Table 1, mean age in the ITT population is reported as 34.6 +/- 10.4 with a footnote indicating that the +/- are SD; however, what does a mean +/- the SD really mean in practical terms? This should not be reported in this manner. Instead, the abstract should be reporting the mean reductions and their 95% confidence intervals; this has a very clear statistical meaning. When reporting the table of characteristics where it is typical to report means and their SDs, the authors should simply report the mean followed by the SD in brackets and indicate so in the footnote, e.g. 34.6 (10.4). It may be common to use the +/- designation in the literature, but because of the inconsistent way in which this is done (some use it to mean ranges, others IQRs, yet others SDs, mostly without clear indication), it is best to avoid this. See <https://journals.plos.org/plosmedicine/article/figure?id=10.1371/journal.pmed.1001594.t001> for an example of how to report means SDs and ranges for descriptive purposes.

Answer: Table 1 as well as the Abstract has been adjusted according to the suggestion from the reviewer. Since the values were not normally distributed the statistician decided that a rank transformation prior to ANOVA was necessary. The ANOVA has thus been run on rank-transformed variables and in our opinion, 95% confidence intervals of the ranks would not be helpful to the reader.

 

Reviewer \#2: Aim of the study was that to evaluate postprandial responses in serum glucose and insulin levels in a cohort of overweight subjects of both genders, treated with a supplement consisting in 2.6 g of amino acids (L-Leucine, L-Threonine, L-Lysine, L-Isoleucine and L-Valine) and 250 mcg of chromium picolinate vs. placebo. In the intention-to-treat-analysis (n = 60), the supplement significantly decreased glucose levels (as iAUC0-120 min, iAUC0-180 min and Cmax), without affecting those of insulin. The treatment was well tolerated.

The study is well designed, and the results are adequately presented. Due to the paucity of biochemical parameters (serum glucose and insulin), the manuscript should be submitted as a rapid communication in a journal of nutrition sciences. Furthermore, some major and minor issues should be solved.

Comments

1\. In the Introduction the rationale has not been clearly reported. In particular, there is no information regarding the reasons for which the Authors chose the specific ingredients of the supplement. For instance, the gastroenteropharmacological properties of the selected amino acids (branched-chain amino acids?) should be mentioned.

Answer: One sentence has been added to the introduction to reference previous work done with the respective ingredients. Furthermore, it is mentioned in the discussion (lines 66-67) that "proteins and amino acids have a distinct effect on gastric emptying, possibly delaying the glucose uptake".

2\. Few biochemical parameters have been measured. Only serum levels of glucose and insulin. To understand the biochemical or pharmacological mechanisms underlying the hypoglycemic effect of the supplement, the Authors should evaluate circulating levels of some gastrointestinal peptides, particularly incretins such as GLP-1, which exert insulinotropic effects and reduce gastric empting. See the article by Rigamonti et al., Nutrients, 2019;11(2). pii: E247. doi: 10.3390/nu11020247.

Answer: No adequate samples are available and thus no further analysis can be made to study effects on gut hormones. However, we are planning to analyze GLP-1 and glucagon in upcoming studies.

3\. The results referring to glycaemia measured with glucometer, which is defined an "imprecise" method by the Authors (pag. 17 -- line 81), should be removed, because they do not add anything.

Answer: Reviewer 3 has an opposing view on this. We have kept the information in the manuscript and added clarification in the Abstract (see comments below).

4\. The Authors should explain the differences in results obtained in the per-protocol analysis vs in the intention-to-treat analysis.

Answer: There are hardly any differences in characteristics between the ITT and PP groups. Thus, the likely explanation for differences in results is assumed to be related to the reduced number of subjects in the PP population.

5\. In the Abstract the Authors should state that subjects were overweight and of both genders. Not only in the conclusions.

Answer: We already stated the number of females and males in the abstract and have added the fact that they were overweight.

6\. The Authors should report the phase of the menstrual cycle during which the experimental tests were performed in female subjects.

Answer: The only data available on menstrual cycle, is the "last date of their menstrual cycle". Unfortunately, no additional data on menstrual cycle was collected. A literature reference and description has been added to the Limitations paragraph in the Discussion.

7\. In the final part of the Discussion, when reporting limitations of the study, the Authors state that fiber content in bread used in the two centers is different. An appropriate statistical analysis should rule out the potential "interfering" effect of this factor.

Answer: We don´t see a point in correcting for fiber differences, since each participant had the same fiber content in both test meals as a consequence of the cross--over design.

8\. Numbers of females/males should be reported in the section of Participants (pag. 4).

Answer: Since the section about Participants on page 4 mainly describe the inclusion and exclusion criteria, we think the better place to specify the number of female and male participants is under the Results section on page 9, so we did.

9\. The exact doses of the single amino acids should be indicated. Not simply 2.6 g of amino acids (L-Leucine, L-Threonine, L-Lysine, L-Isoleucine and L-Valine).

Answer: This information is of sensitive nature and protected by patent. Details have thus not been included in the manuscript. We are in contact with the editorial office to clarify this point.

10\. Pag. 5: protein/fat should be replaced with proteins/fats.

Answer: Has been changed accordingly.

11\. Sensitivity and intra-/inter-assay coefficients of variation of the analytical methods for glucose and insulin should be indicated.

Answer: Information has been added.

12\. Pag. 6; the safety endpoints were evaluated at the three visits. Please, specify these time points.

Answer: Clarification has been added.

13\. Fig. 1 is of low resolution and difficult to read. Please, improve the quality of this figure.

Answer: The resolution has been increased.

14\. Pag. 14 -- Line 1: "Lead" should be "led".

Answer: has been changed accordingly.

15\. Pag. 14 -- Line 16; what are the "other subgroups"? Please, specify.

Answer: has been changed accordingly.

16\. Pag. 14 -- Line 19: The Authors state that adverse events were categorized as possibly related to supplement or placebo. What system of categorization (or algorithm) was used?

Answer: Clarification has been added.

17\. Pag. 15 -- line 33: where was the acronym IGT (impaired glucose tolerance) abbreviated?

Answer: The acronym has been spelled out.

18\. Pag. 16 -- lines 65-68: The Authors discuss the results by citing "unpublished" results. This is scientifically not appropriate.

Answer: The section has been removed.

Reviewer \#3: This clinical trial was designed to evaluate the efficacy of a nutritional supplement to lower blood glucose levels after a meal in health individuals. The study was well-conducted, and the data were clearly described. I only have few comments, but that should be included in the revised manuscript:

1\) A conflicting result is regarding the lack of changes when blood glucose levels were evaluated using glucometers, compared to enzymatic methods that determined serum glucose. The authors argued that regular glucometers used in the present study are imprecise, but I personally think that this argument is not necessarily valid. Anyway, I think that the authors should include the information of the lack of differences in blood glucose levels when using glucometers in the Abstract. Thus, the readers can be informed that the improvement in glucose homeostasis was verified by one method of analysis but was not confirmed by data obtained using glucometers.

Answer: We have added this information accordingly

2\) The adverse events should be described in Results. They are only briefly mentioned without explaining what they refer to.

Answer: This information has been added.

3\) Although I agree that this is not required for this clinical trial, I recommend that the authors measure GI-secreted hormones (e.g., GLP-1, PYY, GIP or ghrelin) during their trials to try to determine whether the supplement could have its effects via humoral mechanisms.

Answer: No adequate samples are available and thus no further analysis can be made to study effects on gut hormones. However, we are planning to analyze GLP-1 and glucagon in upcoming studies.

10.1371/journal.pone.0234237.r003
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13 Mar 2020

PONE-D-19-15766R1

A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study

PLOS ONE

Dear Dr Ostman,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please respond to the Reviewer\'s comments including explanation regarding patent-protected information.

We would appreciate receiving your revised manuscript by Apr 27 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Maciej S. Buchowski

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript is vastly improved since the previous round of peer review, and I commend the authors for taking on board most of the reviewers\' suggestions. There is still one major issue which the authors have not addressed, and a few minor ones which have arisen since the last round.

Major issues:

\- in my comment (6) in the previous round, I made a recommendation on how authors should report means and SDs in the descriptive tables, and group means and SEs in the inference tables, along with effects as between-group differences with their 95% confidence intervals and p-values. The authors have done most of this, but have not reported the 95% confidence intervals for the differences/effects; this is very important and should be done. Even where authors have decided to report effects in relative terms (e.g. 24.7% reduction in venous serum iAUC), a 95% confidence interval for this effect should be reported - although I would generally recommend that you stick to absolute differences in the results and perhaps keep relative differences to the discussion, because your analytical method does not estimate relative differences. Reporting SEs and SDs is not necessary in the abstract, but the 95% confidence intervals are crucial.

\- the authors report some rank transformation technique to calculate p-values due to non-normality of \'values\' (I\'m assuming you mean outcome measures here). Normality of outcomes is not a requisite to report p-values from an ANOVA/regression; it is only the normality of residuals that is assumed.

Other points:

Abstract

\- If you choose to report the SEs in the abstract despite the comment above, please indicate what quantities are in the brackets (in addition to specifying the confidence intervals). Also, consider rephrasing all through to refer to \'differences\' rather than \'reductions\'/\'decreases\' in quantities. For example, you could say: \"\... the supplement resulted in decreased venous blood glucose compared to placebo, mean (SE) of 69.3 (7.2) versus 52.2 (6.4) respectively, a difference of 17.1 mmol/L (95%CI X to Y, p-value x.xxx)\". Please report the exact p-values unless they are less than 0.001.

\- the following phrase is completely inappropriate and should be removed: \"\... missed statistical significance\". It implies that statistical significance is some magical target to be hit or missed which is not the case. You either find evidence of a difference, based on a statistically significant finding, or you don\'t find that evidence; but phraseology such as this suggesting that you aimed to find a difference but missed it is very poor statistical reporting.

Methods

\- p5 line 94: do you mean \"\... a total of 2.6g of five amino acids (L-leucine\...\"

\- p6, \'Outcome measures\': the iAUC-0,120min could still be better described than has been done so far. Does it represent a change in plasma glucose concentration up to 120 minutes after ingestion of the meal/product? If so, describe it as such (or similar terms). Same for the other iAUCs.

\- p8 second paragraph of \'statistical analysis\' - there appears to be an incomplete sentence beginning \"Although simple, the trapezoidal rule\...\"

\- p8 line 178: you mean \"complete observations on 57 individuals\", not complete datasets.

\- p8 line 180: the paragraph on page 9 from line 184 should be moved to the sentence that ends with \"imputation.\" on line 180. After that, the next sentence should begin with p-values, not probabilities, which has a very different meaning in this context.

\- p9 line 187 - see comment above about normality.

\- Table 2 - see comment above about reporting differences with their 95% confidence intervals and p-values

\- p14 line 8 - see comment above about \"missing statistical significance\", which is a very serious and important point about statistical reporting.

Reviewer \#2: The Authors have minimally responded to the Referee's comments.

As no new data have been added in the revised version, the Referee again suggests the Authors to submit the manuscript as a rapid communication to a journal dealing with nutrition and related topics.

The Referee does not hide the disappoint due to the Authors' refusal to report the amounts of amino acids present in the supplement, which the Authors declare to be protected by a patent.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234237.r004

Author response to Decision Letter 1

24 Apr 2020

Reviewer \#1:

This manuscript is vastly improved since the previous round of peer review, and I commend the authors for taking on board most of the reviewers\' suggestions. There is still one major issue which the authors have not addressed, and a few minor ones which have arisen since the last round.

Major issues:

\- in my comment (6) in the previous round, I made a recommendation on how authors should report means and SDs in the descriptive tables, and group means and SEs in the inference tables, along with effects as between-group differences with their 95% confidence intervals and p-values. The authors have done most of this, but have not reported the 95% confidence intervals for the differences/effects; this is very important and should be done. Even where authors have decided to report effects in relative terms (e.g. 24.7% reduction in venous serum iAUC), a 95% confidence interval for this effect should be reported - although I would generally recommend that you stick to absolute differences in the results and perhaps keep relative differences to the discussion, because your analytical method does not estimate relative differences. Reporting SEs and SDs is not necessary in the abstract, but the 95% confidence intervals are crucial.

\- the authors report some rank transformation technique to calculate p-values due to non-normality of \'values\' (I\'m assuming you mean outcome measures here). Normality of outcomes is not a requisite to report p-values from an ANOVA/regression; it is only the normality of residuals that is assumed.

Answer:

We apologize for the imprecision of our last response. The rank transformation had been performed due to non-normality of both the data and the residuals. Ranking data, as was performed in the analysis, is one of the options for handling this issue (1,2). But our statistician advised that presenting the 95% confidence intervals of the non-ranked transformed data with ranked p-values has limited statistical value.

However, we have found that some literature explicitly recommends against examining data and residuals for normality (3), especially since the F-test for sample sizes larger than 20 or 30 where there are equal sample sizes per study arm (which we have) is robust against moderate departures from the assumptions of normality and homogeneity of variances (4). Thus, running the same test without prior ranking is also a plausible option, which would ensure consistency with the confidence interval (i.e. linear mixed model with treatment as main effect, subject number as random effect controlling sequence and period instead of a ranked linear mixed model with treatment as main effect, subject number as random effect controlling sequence and period). As could be expected, the p-values and means derived from this analysis are slightly different from the ranked data, since they are least squared means that have been adjusted for subject random effect, sequence and period. Hence, we have adapted the manuscript accordingly in the text and Table 2.

\(1\) Conover W. J. in Lovric M. International Encyclopedia of Statistical Science: Springer 2011, p. 1184-1193

\(2\) Sawilowsky S. S. Nonparametric tests of interaction in experimental design. Review of Educational Research. 1990; 60: 91-126

\(3\) Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models: Cambridge university press 2006. P 45-46

\(4\) Cohen J. Statistical power analysis for the behavioral sciences. 2 edn: Lawrence Erlbaum Associates, Publishers 1988, p. 407-408

Other points:

Abstract

\- If you choose to report the SEs in the abstract despite the comment above, please indicate what quantities are in the brackets (in addition to specifying the confidence intervals). Also, consider rephrasing all through to refer to \'differences\' rather than \'reductions\'/\'decreases\' in quantities. For example, you could say: \"\... the supplement resulted in decreased venous blood glucose compared to placebo, mean (SE) of 69.3 (7.2) versus 52.2 (6.4) respectively, a difference of 17.1 mmol/L (95%CI X to Y, p-value x.xxx)\". Please report the exact p-values unless they are less than 0.001.

Answer:

The phrasing in the abstract has been revised according to the suggestions.

\- the following phrase is completely inappropriate and should be removed: \"\... missed statistical significance\". It implies that statistical significance is some magical target to be hit or missed which is not the case. You either find evidence of a difference, based on a statistically significant finding, or you don\'t find that evidence; but phraseology such as this suggesting that you aimed to find a difference but missed it is very poor statistical reporting.

Answer:

The phrase has been removed.

Methods

\- p5 line 94: do you mean \"\... a total of 2.6g of five amino acids (L-leucine\...

Answer:

We specify the meaning of 5AA in the introduction and thus think it is appropriate to use that abbreviation when we talk about the exact same blend. Consequently, we kept the text unchanged.

\- p6, \'Outcome measures\': the iAUC-0,120min could still be better described than has been done so far. Does it represent a change in plasma glucose concentration up to 120 minutes after ingestion of the meal/product? If so, describe it as such (or similar terms). Same for the other iAUCs.

Answer:

An extra sentence has been added for clarification.

\- p8 second paragraph of \'statistical analysis\' - there appears to be an incomplete sentence beginning \"Although simple, the trapezoidal rule\...\"

Answer:

We cannot see that the sentence is incomplete but have tried to rephrase to make it more clear.

\- p8 line 178: you mean \"complete observations on 57 individuals\", not complete datasets.

Answer:

The sentence has been rephrased to clarify.

\- p8 line 180: the paragraph on page 9 from line 184 should be moved to the sentence that ends with \"imputation.\" on line 180. After that, the next sentence should begin with p-values, not probabilities, which has a very different meaning in this context.

Answer:

The paragraphs were restructured according to the comment.

\- p9 line 187 - see comment above about normality.

Answer:

Sentence was removed, since statistical method was revised according to Reviewers suggestion.

\- Table 2 - see comment above about reporting differences with their 95% confidence intervals and p-values

Answer:

95% confidence intervals were included.

\- p14 line 8 - see comment above about \"missing statistical significance\", which is a very serious and important point about statistical reporting.

Answer:

The sentences have been rephrased.

Reviewer \#2:

The Authors have minimally responded to the Referee's comments.

As no new data have been added in the revised version, the Referee again suggests the Authors to submit the manuscript as a rapid communication to a journal dealing with nutrition and related topics.

Answer:

The manuscript has been under Review for publication in PLOS one for a very long time after recommendation by the board of PLOS Med. We sincerely hope to qualify for publication now, a novel submission to a different journal would definitely be a non-preferred option. In addition, we believe that PLOSone is the right journal for this study since it allows wide availability to the scientific community in a research area that affects millions of individuals worldwide.

The Referee does not hide the disappoint due to the Authors' refusal to report the amounts of amino acids present in the supplement, which the Authors declare to be protected by a patent.

Answer:

We understand the Reviewers disappointment in this matter; however, we hope that there is some understanding that scientific work and investment of many years needs to be protected from patent infringement. We are very happy to share material or information after publication of the manuscript with individual scientists/researchers upon request.

We thank the Reviewer for working on this manuscript.

###### 

Submitted filename: Response to reviewers_final.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234237.r005
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PONE-D-19-15766R2

Dear Dr. Ostman,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Maciej S. Buchowski

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: No

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Line 135 - the sentence that has been added since the last review does not add any clarity, if anything it makes the description harder to understand. I was hoping for a more \'lay-appropriate\' explanation for what the incremental area-under-the-curve represents. I had previously tempted the authors to add clarity by asking them \"Does it represent a change in plasma glucose concentration over 120 minutes post-ingestion of the product?\" I was hoping that in answering this one way or another, the authors would have been able to explain what this outcome measure represents. This is a missed opportunity, however, I am not inclined to hold up the publication of this excellent piece of research on this account!

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Jose Donato Jr.

10.1371/journal.pone.0234237.r006
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A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study

Dear Dr. Östman:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maciej S. Buchowski

Academic Editor

PLOS ONE
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